Tumor-colonizing bacteria: A potential tumor targeting therapy

  title={Tumor-colonizing bacteria: A potential tumor targeting therapy},
  author={Chao Zu and Jiansheng Wang},
  journal={Critical Reviews in Microbiology},
  pages={225 - 235}
Abstract In 1813, Vautier published his observation of tumor regression in patients who had suffered from gas gangrene. Since then, many publications have described the use of bacteria as antitumor therapy. For example, Bifidobacterium and Clostridium have been shown to selectively colonize tumors and to reduce tumor size. In addition, recent studies have focused on the use of genetic engineering to induce the expression of pro-drug converting enzymes, cytokines, specific antibodies, or suicide… 

Therapy of solid tumors using probiotic Symbioflor-2 – restraints and potential

It is demonstrated that Symbioflor-2 displays a highly specific tumor targeting ability as determined in murine CT26 and RenCa tumor models, and the findings argue for a strategy of safe strain application and a more sustainable use of bacteria as a delivery system for therapeutic molecules.

Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy

Bacterial targeting of tumors has been developed as a unique therapeutic option that meets the ongoing challenges of cancer treatment and can be either used as a monotherapy or in combination with other anticancer therapies for better clinical outcomes.

Bacteria in cancer therapy: beyond immunostimulation

Bacteria employment represents one of the best candidates for cancer treatment because it can surpass barriers with their selective colonization which also has an oncolytic effect by increasing proliferation and immunostimulation in the tumor environment.

Potential of marine bacteria to synthesize bioactive compounds for medical applications

The anticancer potential of cnidarian bacterial symbionts isolated from marine cNidarians to synthesize bioactive compounds against pancreatic cancer was promising, reinforcing the need for deepening its study in the future.

Three-dimensional tumor spheroids for in vitro analysis of bacteria as gene delivery vectors in tumor therapy

Solid three-dimensional multicellular tumor spheroids of the colorectal adenocarcinoma cell line HT-29 were generated and tested for their potential to study prodrug-converting enzyme therapies using bacterial vectors in vitro and indicate that MCTS are a suitable and reliable model to investigate live bacteria as gene delivery vectors for cancer therapy in vitro.

Cancer Immunotherapy: Priming the Host Immune Response with Live Attenuated Salmonella enterica

The role of live attenuated Salmonella enterica as an oncolytic and immunotherapeutic agent, due to its high affinity for tumor tissue and its ability to activate innate and adaptive antitumor immune response is described.

Silver-Nanoparticle-Mediated Therapies in the Treatment of Pancreatic Cancer

This review will focus on the potential use of silver nanoparticles in pancreatic cancer therapy, reporting on a range of different strategies being employed that may be directly applicable in the improvement of clinical outcomes for Pancreatic cancer patients.

Customized materials-assisted microorganisms in tumor therapeutics.

This review has summarized the emerging development of customized materials-assisted microorganisms (MAMO) in tumor therapeutics with an emphasis on the rational utilization of chosen microorganisms and tailored materials, the ingenious design of biohybrid systems, and the efficacious antitumor mechanisms.



Bacteria as tumour-targeting vectors.

Combination bacteriolytic therapy for the treatment of experimental tumors

This work systematically assessed anaerobic bacteria for their capacity to grow expansively within avascular compartments of transplanted tumors and created a strain of C. novyi devoid of its lethal toxin, which has the potential to add a new dimension to the treatment of cancer.

Bacterial therapies: completing the cancer treatment toolbox.

Bacteriolytic therapy can generate a potent immune response against experimental tumors.

It was particularly notable that the induced immune response, when combined with the bacteriolytic effects of C. novyi-NT, could eradicate large established tumors.

Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy.

Therapy with engineered E. coli could significantly improve the results of RT, and could exert a striking inhibitory effect on the development of lung metastasis, according to the results described here.

A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer.

Cp/sod(-)/PVL provides a prototype for a novel class of oncopathic microbes that may have potential for the safe and effective treatment of pancreatic cancer and other poorly vascularized tumors.

Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth

Evidence is provided that nonvirulent bacteria can be exploited as targeting vehicles for local generation of therapeutic proteins in tumors by engineering such bacteria to improve their oncolytic activity by stably inserting a gene encoding LIGHT, a cytokine known to promote tumor rejection.

IL-18-producing Salmonella inhibit tumor growth

Antitumor activity was associated with increased accumulation of T-lymphocytes and NK cells in tumors, and massive infiltration of granulocytes, as well as increased intra-tumoral production of several cytokines, suggesting a novel strategy for cancer immunotherapy.

Inhibition of Tumor Growth Using Salmonella Expressing Fas Ligand

Preclinical results raise the possibility that using attenuated S. typhimurium to deliver FasL to tumors may be an effective and well-tolerated therapeutic strategy for some cancers.

Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors

A new approach for targeting gene therapy to poorly vascularized regions of tumors is described, which employs an attenuated strain of the non-pathogenic bacterium, Salmonella typhimurium, carrying an exogenous gene under the regulation of a new, highly hypoxia-inducible promoter (FF+20*).